by Society of Infectious Diseases Pharmacists
Email Addresses
1 available
Phone Numbers
0 available
April 25, 2025
<p>Dr. Jeannette Bouchard is joined by experts Dr. Romney Humphries, Emily Fox, and Matt Miller to discuss the hot topic of blood culture stewardship and the details of how these experts persevered through the recent blood culture bottle shortage that caused chaos throughout health care institutions at the end of 2024! This medical education was provided by an education grant from bioMerieux.</p> <p>References:</p> <ol> <li>Fabre BCx Stewardship Article doi: 10.1128/JCM.01005-21</li> <li>ED Bcx Stewardship doi: 10.1016/j.ajic.2024.04.198</li> <li>CT Surgery Stewardship doi: 10.1093/icvts/ivaf005</li> <li>Every Crisis is an Opportunity doi: 10.1093/ofid/ofae479</li> <li>Fun IV Coconut Water from I Feel Nerdy section: <a href="https://dr-martins.com/wp-content/uploads/2015/07/2000_the-intravenous-use-of-coconut-water.pdf" rel="nofollow">https://dr-martins.com/wp-content/uploads/2015/07/2000_the-intravenous-use-of-coconut-water.pdf</a></li> </ol>
April 11, 2025
<p>Drs. Pier Giorgio Cojutti and Navaneeth Narayanan join Dr. Megan Klatt to break down what you need to know about amoxicillin/clavulanate dosing. Tune in to learn more about the PK/PD of amoxicillin and clavulanic acid, how we landed on certain ratios for the treatment of common infections, strategies to optimize dosing for serious infections, and more!</p> <p>References:</p> <ol> <li>Oral amoxicillin and amoxicillin-clavulanic acid: properties, indications and usage. Clin Microbiol Infect. 2020 Jul;26(7):871-879. doi: 10.1016/j.cmi.2019.11.028. Epub 2019 Dec 4. PMID: 31811919. </li> <li>New formulations of amoxicillin/clavulanic acid: a pharmacokinetic and pharmacodynamic review. Clin Pharmacokinet. 2005;44(11):1097-115. doi: 10.2165/00003088-200544110-00001. PMID: 16231964.</li> <li>Non-linear absorption pharmacokinetics of amoxicillin: consequences for dosing regimens and clinical breakpoints. J Antimicrob Chemother. 2016 Oct;71(10):2909-17. doi: 10.1093/jac/dkw226. Epub 2016 Jun 20. PMID: 27330071.</li> <li>Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent. J Antimicrob Chemother. 2004 Jan:53 Suppl 1:i3-20. doi: 10.1093/jac/dkh050. PMID: 14726431.</li> <li>Is the standard dose of amoxicillin-clavulanic acid sufficient? BMC Pharmacol Toxicol. 2014 Jul 21:15:38. doi: 10.1186/2050-6511-15-38. PMID: 25047044.</li> <li>MIC of amoxicillin/clavulanate according to CLSI and EUCAST: discrepancies and clinical impact in patients with bloodstream infections due to Enterobacteriaceae. J Antimicrob Chemother. 2017 May 1;72(5):1478-1487. doi: 10.1093/jac/dkw562. PMID: 28093484.</li> <li>Amoxicillin-Clavulanate Breakpoints Against Enterobacterales: Rationale for Revision by the Clinical and Laboratory Standards Institute. Clin Infect Dis. 2024 Aug 16;79(2):516-523. doi: 10.1093/cid/ciae201. PMID: 38626241.</li> <li>Amoxicillin-Clavulanate Breakpoints Against Haemophilus influenzae: Rationale for Revision by the Clinical and Laboratory Standards Institute. Clin Infect Dis. 2025 Feb 24;80(2):481-482. doi: 10.1093/cid/ciae246. PMID: 38709848.</li> <li>No evidence of difference in mortality with amoxicillin versus co-amoxiclav for hospital treatment of community-acquired pneumonia. J Infect. 2024 Jun;88(6):106161. doi: 10.1016/j.jinf.2024.106161. Epub 2024 Apr 23. PMID: 38663754.</li> <li>Population pharmacokinetics and dosing simulations of amoxicillin in obese adults receiving co-amoxiclav. J Antimicrob Chemother. 2020 Dec 1;75(12):3611-3618. doi: 10.1093/jac/dkaa368. PMID: 32888018.</li> <li>Comprehensive guidance for antibiotic dosing in obese adults: 2022 update. Pharmacotherapy. 2023 Mar;43(3):226-246. doi: 10.1002/phar.2769. Epub 2023 Feb 18. PMID: 36703246.</li> </ol>
March 28, 2025
<p>Dr. Brent Richards joins Dr. Erin McCreary to discuss the growing capability for artificial intelligence (AI) and big data in the healthcare industry. What is AI and machine learning, how can these tools enhance patient care, and what can we expect in the future from this space? Listen to Breakpoints on <a href="https://clicktime.symantec.com/3R8uEM1294vdh21uL7nDhi37VN?u=https%3A%2F%2Furldefense.proofpoint.com%2Fv2%2Furl%3Fu%3Dhttps-3A__urldefense.com_v3_-5F-5Fhttps-3A_sidp.org_EmailTracker_LinkTracker.ashx-3FlinkAndRecipientCode-3DD0L0Q0-2A2f7TCFxVOgWn67jW1UJdXCNI8Kg8JiVOalanWSnv86s3-2A2feIgSCp0yFQqON7208n7OVg3dZANuq14i1FyBxNlUE-2A2fEuorj-2A2bQth-2A2f-2A2fdOz0-2A3d-5F-5F-3BJSUlJSUlJQ-21-21NHLzug-21dngq5xycWCrDGial95M7tI5UvZ0hrj1je4zdNccDjhDKN5XA2UTqa18K5AmJP8qJ0DM-2524%26d%3DDwMFaQ%26c%3DeuGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM%26r%3DY8YtMys67u8RazcRiw-k49ag18dzD_0nTpHmfvVASdo%26m%3DXdaKjGMXuOKRQDNGYMG_peUNwKP87ezW6gBVWYRNwCs%26s%3DnaJ94CqlnGko8PYcHx7P0a2ORkqJjTTXTXo3of9toOI%26e%3D" rel="nofollow">iTunes</a>, <a href="https://clicktime.symantec.com/3UPSKiX9zWTmFRi5JvbYYuF7VN?u=https%3A%2F%2Furldefense.proofpoint.com%2Fv2%2Furl%3Fu%3Dhttps-3A__urldefense.com_v3_-5F-5Fhttps-3A_sidp.org_EmailTracker_LinkTracker.ashx-3FlinkAndRecipientCode-3DuVw7WrCV3UsT9jQEoMx19bCJk8wSnOrHKsz-2A2fiDg5jIJz-2A2fPmlAAnjeQMczcZNKe65FwcZB1GSntOoUYpImtNgtdyfUUiYEctoWEc5okmtqjI-2A3d-5F-5F-3BJSUl-21-21NHLzug-21dngq5xycWCrDGial95M7tI5UvZ0hrj1je4zdNccDjhDKN5XA2UTqa18K5AmJSsDRBjw-2524%26d%3DDwMFaQ%26c%3DeuGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM%26r%3DY8YtMys67u8RazcRiw-k49ag18dzD_0nTpHmfvVASdo%26m%3DXdaKjGMXuOKRQDNGYMG_peUNwKP87ezW6gBVWYRNwCs%26s%3DiSHbkOT6yU9AfKVXVzZYoT6ihqn4rV7u2MtsJu0S4M0%26e%3D" rel="nofollow">Overcast</a>, <a href="https://clicktime.symantec.com/3PoPyJU9wVY1CeG5JSoJ5TF7VN?u=https%3A%2F%2Furldefense.proofpoint.com%2Fv2%2Furl%3Fu%3Dhttps-3A__urldefense.com_v3_-5F-5Fhttps-3A_sidp.org_EmailTracker_LinkTracker.ashx-3FlinkAndRecipientCode-3D-2A2b6F4mrvzRMOPk-2A2ba-2A2bOlEsgbBTfXcxd55wOs9FeTrvlo4ldPpqgt3wD8-2A2fE3HTFftwPVPPM-2A2b6cPP8AXhMlUJL-2A2fVJcCllOYuUjVjRDDAWZ7AIEA-2A3d-5F-5F-3BJSUlJSUlJQ-21-21NHLzug-21dngq5xycWCrDGial95M7tI5UvZ0hrj1je4zdNccDjhDKN5XA2UTqa18K5AmJznOuBy8-2524%26d%3DDwMFaQ%26c%3DeuGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM%26r%3DY8YtMys67u8RazcRiw-k49ag18dzD_0nTpHmfvVASdo%26m%3DXdaKjGMXuOKRQDNGYMG_peUNwKP87ezW6gBVWYRNwCs%26s%3D2k6k5CxoFMUsUIyOPzQO6SsDBdBx1NhRPK1AYDToK7g%26e%3D" rel="nofollow">Spotify</a>, <a href="https://clicktime.symantec.com/3EzDPdcsg2aGkG24TqSDnQD7VN?u=https%3A%2F%2Furldefense.proofpoint.com%2Fv2%2Furl%3Fu%3Dhttps-3A__urldefense.com_v3_-5F-5Fhttps-3A_sidp.org_EmailTracker_LinkTracker.ashx-3FlinkAndRecipientCode-3DSMv1IUOMa6BBtA9x3UJdt0xL08TAUa63rcUQgIHTRk5z0skO9IEnaSqnkGdDVELU4LHF4xYo6n4QprSv5REh8CiWi24tVPHxui-2A2fuqe-2A2bSTcY-2A3d-5F-5F-3BJSUl-21-21NHLzug-21dngq5xycWCrDGial95M7tI5UvZ0hrj1je4zdNccDjhDKN5XA2UTqa18K5AmJgDogjBg-2524%26d%3DDwMFaQ%26c%3DeuGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM%26r%3DY8YtMys67u8RazcRiw-k49ag18dzD_0nTpHmfvVASdo%26m%3DXdaKjGMXuOKRQDNGYMG_peUNwKP87ezW6gBVWYRNwCs%26s%3Dg4LAADo6MhO--d9qoDcdunhQOKfhr7JZ5QH6liBGX1w%26e%3D" rel="nofollow">Listen Notes</a>, <a href="https://clicktime.symantec.com/3K5DQtmVxCMwmFfYTXFqors7VN?u=https%3A%2F%2Furldefense.proofpoint.com%2Fv2%2Furl%3Fu%3Dhttps-3A__urldefense.com_v3_-5F-5Fhttps-3A_sidp.org_EmailTracker_LinkTracker.ashx-3FlinkAndRecipientCode-3DVTJG9hRIZySdc5y4-2A2bhe4mxglJA6g9BcwePDuINOrGkp6xW-2A2brG3A2kq5lxBfriwS6WTOLOSeS4ISBSaSBKW5soT53zrLCvjBMOj4J11xQuOQ-2A3d-5F-5F-3BJSUl-21-21NHLzug-21dngq5xycWCrDGial95M7tI5UvZ0hrj1je4zdNccDjhDKN5XA2UTqa18K5AmJgJndlwc-2524%26d%3DDwMFaQ%26c%3DeuGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM%26r%3DY8YtMys67u8RazcRiw-k49ag18dzD_0nTpHmfvVASdo%26m%3DXdaKjGMXuOKRQDNGYMG_peUNwKP87ezW6gBVWYRNwCs%26s%3D8zQ_WQmmq_ADO_yxCG2pCmfPHOXyBOt3Tvd8SLzw0ZM%26e%3D" rel="nofollow">Player FM</a>, <a href="https://clicktime.symantec.com/3WCdXn4P2EkTbSZz3j2efpW7VN?u=https%3A%2F%2Furldefense.proofpoint.com%2Fv2%2Furl%3Fu%3Dhttps-3A__urldefense.com_v3_-5F-5Fhttps-3A_sidp.org_EmailTracker_LinkTracker.ashx-3FlinkAndRecipientCode-3DRuxN50dhXQmkw9mJ-2A2fIv1BwOldEM8lu6wJn-2A2bp-2A2bFH1TNKc-2A2fH8BYSR8y8gvYx02jfY5q57aOItrIB31hBXqNyioCeEXlh0uZxM-2A2b7yda7rBp-2A2bnQ-2A3d-5F-5F-3BJSUlJSUlJQ-21-21NHLzug-21dngq5xycWCrDGial95M7tI5UvZ0hrj1je4zdNccDjhDKN5XA2UTqa18K5AmJdwUkjek-2524%26d%3DDwMFaQ%26c%3DeuGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM%26r%3DY8YtMys67u8RazcRiw-k49ag18dzD_0nTpHmfvVASdo%26m%3DXdaKjGMXuOKRQDNGYMG_peUNwKP87ezW6gBVWYRNwCs%26s%3Dph48oB1hX73YsIdjGLx2gcMvE6IA7KTEWazW2Gb_tGg%26e%3D" rel="nofollow">Pocket Casts</a>, <a href="https://clicktime.symantec.com/3HAZ1dAKjokvr2fVP1FEFmZ7VN?u=https%3A%2F%2Furldefense.proofpoint.com%2Fv2%2Furl%3Fu%3Dhttps-3A__urldefense.com_v3_-5F-5Fhttps-3A_sidp.org_EmailTracker_LinkTracker.ashx-3FlinkAndRecipientCode-3DHM5q-2A2bqjVNHXHSuzhQfgDHnfYMTayJY5I54xK583XQlZuSY-2A2fiukAdy7bGkpDwwp4DsXAS8nTuZi2kow5ilRLCsjmfJitQC61ab1gmhUelJY4-2A3d-5F-5F-3BJSUl-21-21NHLzug-21dngq5xycWCrDGial95M7tI5UvZ0hrj1je4zdNccDjhDKN5XA2UTqa18K5AmJpiKf8vY-2524%26d%3DDwMFaQ%26c%3DeuGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM%26r%3DY8YtMys67u8RazcRiw-k49ag18dzD_0nTpHmfvVASdo%26m%3DXdaKjGMXuOKRQDNGYMG_peUNwKP87ezW6gBVWYRNwCs%26s%3Dl98Xj6atbJE3Bl9nQFR0NxeCSObWEBXn2QRprS9VAPM%26e%3D" rel="nofollow">TuneIn</a>, <a href="https://clicktime.symantec.com/3Uc5sj35HuHzBtN9qsZELaz7VN?u=https%3A%2F%2Furldefense.proofpoint.com%2Fv2%2Furl%3Fu%3Dhttps-3A__urldefense.com_v3_-5F-5Fhttps-3A_sidp.org_EmailTracker_LinkTracker.ashx-3FlinkAndRecipientCode-3DGDsckAp3VJZvS-2A2b-2A2bFQBnNnris8ulgVAn4tAgxp4bAnDy-2A2bDLqT7z-2A2btergfEsE7sz7-2A2fi9-2A2bFF54K4LSozTCeCmh8VOosKkqijPiN5VAKc79XwEk-2A3d-5F-5F-3BJSUlJSUlJQ-21-21NHLzug-21dngq5xycWCrDGial95M7tI5UvZ0hrj1je4zdNccDjhDKN5XA2UTqa18K5AmJoMTwltw-2524%26d%3DDwMFaQ%26c%3DeuGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM%26r%3DY8YtMys67u8RazcRiw-k49ag18dzD_0nTpHmfvVASdo%26m%3DXdaKjGMXuOKRQDNGYMG_peUNwKP87ezW6gBVWYRNwCs%26s%3DOqwdj1qqIUl3AHO7g0LP6TxXzSXeXUX4Ce_Sv_hRfyw%26e%3D" rel="nofollow">Blubrry</a>, <a href="https://clicktime.symantec.com/3Dfmv5CECYNRhGAwqZ5sQdY7VN?u=https%3A%2F%2Furldefense.proofpoint.com%2Fv2%2Furl%3Fu%3Dhttps-3A__urldefense.com_v3_-5F-5Fhttps-3A_sidp.org_EmailTracker_LinkTracker.ashx-3FlinkAndRecipientCode-3DQ7W-2A2bjxudl-2A2biTqflXrhVsrXi0r-2A2fptIhwKQytXBX17a9V2Op9GnTA1RTRGL19e54xgVdZSW-2A2bJeLiR7wWXkwDiSYgglUPHsNsGqAu6xuhXPp6o-2A3d-5F-5F-3BJSUlJSU-21-21NHLzug-21dngq5xycWCrDGial95M7tI5UvZ0hrj1je4zdNccDjhDKN5XA2UTqa18K5AmJzCo9rGw-2524%26d%3DDwMFaQ%26c%3DeuGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM%26r%3DY8YtMys67u8RazcRiw-k49ag18dzD_0nTpHmfvVASdo%26m%3DXdaKjGMXuOKRQDNGYMG_peUNwKP87ezW6gBVWYRNwCs%26s%3DnBRVi03Hc0KelEEqohO2GHfC96p04Pkm8F2eHsswsZY%26e%3D" rel="nofollow">RadioPublic</a>, or by using our RSS feed: <a href="https://sidp.pinecast.co/" rel="nofollow">https://sidp.pinecast.co/</a>. Visit our website! <a href="https://breakpoints-sidp.org/" rel="nofollow">https://breakpoints-sidp.org/</a></p>
Sara Dong
Vincent Racaniello
Infectious Disease: Insights of Two Specialists
American College of Physicians
Core IM Team
JAMA Network
The Curious Clinicians
The Curbsiders Internal Medicine Podcast
Scott D. Weingart, MD FCCM
Infectious Diseases Society of America (IDSA)
Adam Thomas & Josh Farkas
Vincent Racaniello
Eric Christianson, PharmD; Pharmacology Expert and Clinical Pharmacist
The Clinical Problem Solvers
Vincent Racaniello
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at [email protected] for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.